CoChat
Sign Up
Cited by 54

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

What makes a blood cell based miRNA expression pattern disease specific? - A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls

Leidinger, Petra, Backes, Christina, Dahmke, Indra N., Galata, Valentina, Huwer, Hanno, Stehle, Ingo, Bals, Robert, Keller, Andreas, Meese, Eckart·2014·Oncotarget
DOI 10.18632/oncotarget.2419PMC PMC4253448
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2419

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Heatmap using the 50 miRNAs with the highest variance over all analyzed samples Figure (A) shows the heatmap for all samples analyzed together. The color of the bar under the dendrogram indicates the cells with common myeloid (blue) and common lymphoid (red) progenitor. Figure (B) shows the heatmap for the healthy individuals and Figure (C) for the lung cancer patients. Here the color of the bar under the dendrogram indicates whole blood samples (blue) and the single immune cell subtypes (red). The single cell types are also indicated by the coloured bar at the bottom of the figure (blue=whole blood, red=monocytes CD14+, green=granulocytes CD15+, grey= B-cells CD19+, yellow=T-cells CD3+, purple=NK-cells CD56+).
Figure 1 Heatmap using the 50 miRNAs with the highest variance over all analyzed samples Figure (A) shows the heatmap for all samples analyzed together. The color of the bar under the dendrogram indicates the cells with common myeloid (blue) and common lymphoid (red) progenitor. Figure (B) shows the heatmap for the healthy individuals and Figure (C) for the lung cancer patients. Here the color of the bar under the dendrogram indicates whole blood samples (blue) and the single immune cell subtypes (red). The single cell types are also indicated by the coloured bar at the bottom of the figure (blue=whole blood, red=monocytes CD14+, green=granulocytes CD15+, grey= B-cells CD19+, yellow=T-cells CD3+, purple=NK-cells CD56+).CC BY · PubMed Central
Figure 2 Venn diagram showing the leukocyte subset specific miRNAs The dark grey circle shows the cell subset specific miRNAs in lung cancer samples and the light grey circle shows the cell subset specific miRNAs in control samples. The overlap indicates the miRNAs that were found to be subtype specific in both sample groups. A list of the miRNAs is given in Supplemental Table 1.
Figure 2 Venn diagram showing the leukocyte subset specific miRNAs The dark grey circle shows the cell subset specific miRNAs in lung cancer samples and the light grey circle shows the cell subset specific miRNAs in control samples. The overlap indicates the miRNAs that were found to be subtype specific in both sample groups. A list of the miRNAs is given in Supplemental Table 1.CC BY · PubMed Central
Figure 3 Venn diagram with the miRNAs indicative for blood cell origin, line of defense, and function We identified the miRNAs deregulated between cells with common myelod progenitor and common lyphoid progenitor (A), cells of the innate immune system and the adaptive immune system (B), as well as antigen presenting cells and cytotoxic cells (C) for lung cancer patients (dark grey circles) and healthy individuals (light gray circles), respectively. The miRNAs specific in the comparisons for lung cancer sapmles are listed in the boxes on the left, miRNAs specific in the comparisons for healthy individuals are listed in the boxes on the right. The number of miRNAs that were deregulated in lung cancer samples and healthy individuals are indicated by the overlap of the circles.
Figure 3 Venn diagram with the miRNAs indicative for blood cell origin, line of defense, and function We identified the miRNAs deregulated between cells with common myelod progenitor and common lyphoid progenitor (A), cells of the innate immune system and the adaptive immune system (B), as well as antigen presenting cells and cytotoxic cells (C) for lung cancer patients (dark grey circles) and healthy individuals (light gray circles), respectively. The miRNAs specific in the comparisons for lung cancer sapmles are listed in the boxes on the left, miRNAs specific in the comparisons for healthy individuals are listed in the boxes on the right. The number of miRNAs that were deregulated in lung cancer samples and healthy individuals are indicated by the overlap of the circles.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 39

  1. Enright, 2006, miRBase: microRNA sequences, targets and gene nomenclature, Nucleic Acids Res, 34, D140
  2. Griffiths-Jones, miRBase: integrating microRNA annotation and deep-sequencing data, Nucleic Acids Res, 39, D152
  3. Agami, 2011, MicroRNA regulation by RNA-binding proteins and its implications for cancer, Nat Rev Cancer, 11, 644, 10.1038/nrc3107 · DOI · Paper page
  4. Mendell, 2006, A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes, Oncogene, 25, 6188, 10.1038/sj.onc.1209913 · DOI
  5. Slack, 2006, Oncomirs - microRNAs with a role in cancer, Nat Rev Cancer, 6, 259, 10.1038/nrc1840 · DOI · Paper page
  6. Cho, 2007, OncomiRs: the discovery and progress of microRNAs in cancers, Mol Cancer, 6, 60, 10.1186/1476-4598-6-60 · DOI
  7. Croce, 2009, Causes and consequences of microRNA dysregulation in cancer, Nat Rev Genet, 10, 704, 10.1038/nrg2634 · DOI
  8. Meese, 2011, Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients, Molecular bioSystems, 7, 3187, 10.1039/c1mb05353a · DOI
  9. Ruprecht, 2011, Toward the blood-borne miRNome of human diseases, Nature methods, 8, 841, 10.1038/nmeth.1682 · DOI · Paper page
  10. Meese, 2009, miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments, BMC Cancer, 9, 353, 10.1186/1471-2407-9-353 · DOI
  11. Meese, 2011, Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis, RNA Biol, 8, 506, 10.4161/rna.8.3.14994 · DOI
  12. Meese, 2012, MicroRNA expression changes after lung cancer resection: A follow-up study, RNA Biol, 9, 900, 10.4161/rna.20107 · DOI
  13. Meese, 2011, Specific peripheral miRNA profiles for distinguishing lung cancer from COPD, Lung Cancer, 74, 41, 10.1016/j.lungcan.2011.02.003 · DOI
  14. Meese, 2012, MicroRNAs - Important Molecules in Lung Cancer Research, Front Genet, 2, 104
  15. Jemal, 2013, Cancer statistics, 2013, CA Cancer J Clin, 63, 11, 10.3322/caac.21166 · DOI · Paper page
  16. Pacheco, 2012, Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression, PLoS One, 7, e29979, 10.1371/journal.pone.0029979 · DOI
  17. Benz, 2010, Comprehensive microRNA expression profiling of the hematopoietic hierarchy, Proc Natl Acad Sci U S A, 107, 15443, 10.1073/pnas.1009320107 · DOI
  18. Kieda, 2013, MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response, Arch Immunol Ther Exp (Warsz), 61, 285, 10.1007/s00005-013-0231-4 · DOI
  19. Hochberg, 1988, A sharper bonferroni procedure for multiple tests of significance, Biometrica, 75, 185, 10.1093/biomet/75.4.800 · DOI · Paper page
  20. Golani, 2001, Controlling the false discovery rate in behavior genetics research, Behav Brain Res, 125, 279, 10.1016/S0166-4328(01)00297-2 · DOI · Paper page
  21. Coussens, 2006, Paradoxical roles of the immune system during cancer development, Nat Rev Cancer, 6, 24, 10.1038/nrc1782 · DOI
  22. Tanabe, 2007, Cancer immunoediting from immune surveillance to immune escape, Immunology, 121, 1, 10.1111/j.1365-2567.2007.02587.x · DOI
  23. Speiser, 2012, The three main stumbling blocks for anticancer T cells, Trends Immunol, 33, 364, 10.1016/j.it.2012.02.006 · DOI
  24. Whiteside, 2013, Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?, Cancer Immunol Immunother
  25. Sakaguchi, 2010, Regulatory T cells in tumor immunity, Int J Cancer, 127, 759, 10.1002/ijc.25429 · DOI · Paper page
  26. Shu, 2010, MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis, J Cancer Res Clin Oncol, 137, 557
  27. Lianidou, 2013, Clinical evaluation of microRNA expression profiling in non small cell lung cancer, Lung Cancer, 81, 388, 10.1016/j.lungcan.2013.05.007 · DOI
  28. Shu, 2011, Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer, Chin J Cancer, 30, 407, 10.5732/cjc.010.10522 · DOI
  29. De, 2011, Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer, J Surg Oncol, 104, 847, 10.1002/jso.22008 · DOI
  30. Pothof, 2014, DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity, Molecular oncology, 8, 458, 10.1016/j.molonc.2013.12.011 · DOI
  31. Harris, 2012, Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer, Int J Cancer, 130, 1378, 10.1002/ijc.26153 · DOI
  32. Zhou, 2013, miR-150 blocks MLL-AF9-associated leukemia through oncogene repression, Mol Cancer Res, 11, 912, 10.1158/1541-7786.MCR-13-0002-T · DOI
  33. Rajewsky, 2007, MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb, Cell, 131, 146, 10.1016/j.cell.2007.07.021 · DOI
  34. Xu, 2013, miR-150 promotes the proliferation of lung cancer cells by targeting P53, FEBS Lett, 587, 2346, 10.1016/j.febslet.2013.05.059 · DOI
  35. Gao, 2012, Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features, Oncol Rep, 29, 704
  36. Isacke, 2009, A HaemAtlas: characterizing gene expression in differentiated human blood cells, Blood, 113, e1, 10.1182/blood-2008-06-162958 · DOI
  37. Gretz, 2011, miRWalk- database: prediction of possible miRNA binding sites by “walking” the genes of three genomes, Journal of biomedical informatics, 44, 839, 10.1016/j.jbi.2011.05.002 · DOI
  38. Lenhof, 2007, GeneTrail—advanced gene set enrichment analysis, Nucleic Acids Research, 35
  39. Kanehisa, 2002, The KEGG database, Novartis Found Symp, 247, 91, 10.1002/0470857897.ch8 · DOI

Cited by

Sorted by citations

Metadata

Authors
Leidinger, P., Backes, C., Dahmke, I. N., Galata, V., Huwer, H., Stehle, I., Bals, R., Keller, A., & Meese, E.
Affiliations
  • Institute of Human Genetics, Medical School, Saarland University, Building 60, 66421 Homburg/Saar, Germany
  • Department of Clinical Bioinformatics, Saarland University, Building E2.1, 66123 Saarbrücken, Germany
  • Institute for Clinical and Experimental Surgery, Saarland University, Building 65, 66421 Homburg/Saar, Germany
  • Department of Thoracic Surgery, Voelklingen Heart Center, 66333 Voelklingen Germany
  • Department of Pneumology, Medical School, Saarland University, Building 91, 66421 Homburg/Saar, Germany
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2014-09-19
Volume
5
Issue
19
Pages
9484-9497
ISSN
1949-2553
DOI
10.18632/oncotarget.2419
PMC
PMC4253448
Cited by
54
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review